The government has expressed interest in introducing an oral antiviral drug for COVID-19 by the end of the year, with Prime Minister Fumio Kishida saying that such treatments could become a “key trump card” in the prolonged, uphill battle against the coronavirus.
Étiqueté : médicament
As winter approaches and colder weather makes it even more difficult to adhere to social distancing measures, the odds of COVID-19 spreading still further seem to be inevitable. Still, despite having the highest infection rate in the world, there is growing optimism in the United States, thanks to the prospect of effective vaccines being developed in the not-too-distant future.
Experts cast doubt over claims by officials in the city of Osaka that a gargling medicine could help treat coronavirus patients, even as shelves across Japan were stripped clean of popular brands. There’s not enough evidence to support Gov. Hirofumi Yoshimura’s claim that gargling with diluted povidone-iodine could prevent mild coronavirus patients from falling seriously ill, Toshio Nakagawa, chairman of the Japan Medical Association, told reporters Wednesday. The World Health Organization Center for Health Development also added to skepticism.
The Japanese health ministry has authorized the anti-inflammatory drug dexamethasone to treat severe cases of COVID-19 after the inexpensive steroid lowered fatalities by roughly a third in a British trial, marking the second time a candidate has won fast-track approval.
Japanese drugmakers are accelerating their development of vaccines for the novel coronavirus even as foreign rivals seem to be leading the global race, with the government pushing homegrown efforts to secure stable supplies for the country.
Début avril, l’équipe composée des chercheurs de l’Université et de l’hôpital Chang Gung, de l’Academia Sinica, du centre médical du ministère de la Défense et de l’Université Oxford avaient identifié 25 anticorps monoclonaux sur les patients atteints du Covid-19. Aujourd’hui, l’hôpital Chang Gung annonce avoir trouvé un anticorps monoclonal capable d’empêcher le virus du SARS-CoV-2 de pénétrer dans le corps humain avec une capacité de l’inhiber allant de 90% à 98%.
The lead researcher in the trial being conducted for the flu drug Avigan said it’s too early to make a call on whether it works on COVID-19 and patients are still being enrolled.
The lack of results have raised doubts about its approval by the end of this month
Avigan, a candidate drug for treating COVID-19, has not shown apparent efficacy in treating the respiratory disease in clinical trials so far, raising doubts about its approval by the end of this month as sought by the government, sources familiar with the matter said Tuesday.
In the global hunt for coronavirus treatments, a Japanese antiviral medicine known as Avigan has won plaudits from Prime Minister Shinzo Abe and $128 million in government funding.
Prime Minister Shinzo Abe said Monday that Japan will soon approve the anti-viral drug remdesivir for the treatment of coronavirus patients, in what will be the country’s first such decision amid the pandemic.